Motiva Flora Tissue Expander PMCF
← catalyst calendarSponsored by Establishment Labs (industry) · ESTA — their whole pipeline →.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
136estimated
Sites
5
Countries
Chile, Costa Rica, Panama +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-12-14 | actual | When the study began enrolling |
| Primary completion | 2024-12-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-15 | estimated | The whole study's end, after follow-up |
| First posted | 2022-07-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-08-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Breast Tissue Accessory
- Breast Cancer
Intervention
- Device: Breast Tissue Expander — also filed as Motiva Flora Tissue Expander
Primary outcomes
what the primary-completion date above is the date OFIncidence of the device and procedure-related adverse events
measured 6 months follow-up
Perceived success of breast tissue expansion
measured 6 months follow-up
Expected completion of breast tissue expansion
measured Up to 6 months follow-up
Satisfaction assessed by the 5 point Likert scale
measured 6 months follow-up
Permalink · ESTA's whole pipeline · Catalyst calendar · Every registered study · What changed